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    H e a l t h y  r u m i n a n t s  c a r r y  i n t estinal  Shiga  toxin  (Stx)-　
producing  Escherichia  coli ( S T E C ) .  S t x  h a s  a n t i v i r a l  
activities i n  v i t r o  a n d  S T E C  n u m b e r s  c o r r e l a t e  w i t h  
reduced  early  viremia  in  sheep  experimentally  infected 
with bovine leukemia virus (BLV). This study assessed the 
impact of intestinal STEC on BLV-induced disease for one 
year post-BLV-challenge. High STEC scores (CFU/g feces × 
frequency of STEC-positive samples) correlated with good 
health,  whereas  poor  weight  gain,  distress,  and  tumor 
development  occurred  only  among  animals  with  low 
STEC scores. STEC carriage was associated with increased 
percentages of B cells in peripheral blood. 
Keywords: bovine leukemia virus, sheep, Shiga toxin-producing 
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Introduction 
  Some serotypes of Shiga toxin (Stx)-producing Escherichia 
coli (STEC) such as O157：H7 can cause severe illness in 
humans in which toxin(s) cause systemic damage [4,11]. 
However, healthy ruminants carry intestinal STEC [1-3] 
with high prevalence. It is not known what, if any, are the 
benefits of Stx genes or proteins for the bacteria or their 
ruminant hosts. Stxs belong to a family of ribosome- 
inactivating proteins (RIPs) prevalent among plants [7]. 
RIPs are important in the innate plant defense against virus 
infection [19], and are active in vitro against animal cells 
harboring retroviruses [10,17]. Stxs are not detrimental to 
normal bovine cells, but inhibit expression and replication 
of bovine leukemia virus (BLV), bovine immunodeficiency 
virus, and equine infectious anemia virus, in cell culture 
[8,10]. We hypothesize that intestinal STEC have an 
antiviral effect in ruminants and compared viral loads with 
intestinal STEC in sheep experimentally infected with BLV. 
In contrast to cattle (that may take 10 years to manifest 
disease symptoms), sheep are a good experimental model 
because they exhibit rapid progression of BLV disease with 
clinical symptoms in 6∼12 months [6,14]. Previously, we 
showed that early BLV viremia is reduced in sheep carrying 
intestinal STEC at 10
4 CFU/g feces [9]. Here we examined 
the impact of intestinal STEC in the late stages (12 to 14 
months) of disease. 
Materials and Methods 
Experimental animals
  All animal procedures were approved by the University 
of Idaho Animal Care and Use Committee. Twenty white- 
face Suffolk wethers were divided into four groups with 5 
animals, as described previously [9], and fed a maintenance 
diet of alfalfa hey ad libitum. Animals were weighed and 
bled post-BLV challenge weekly for the first 9 weeks, 
monthly until 6 months, and then quarterly. Beginning at 4 
months post challenge, general health was assessed 
bi-weekly by two observers (blind to group assignation). 
Animals consistently exhibiting at least 2 of 3 symptoms of 
distress (apathy, poor posture, or an uncertain “shuffling” 
gait) were considered in poor health. 
STEC treatment and enumeration
  Sheep can sporadically carry naturally acquired STEC. 
Thus, although some sheep were treated with oral STEC, 
all sheep carried naturally occurring STEC that were not 
distinguishable from the dosed strains by our culture 
procedure. Nonetheless, all sheep were given oral doses of 
5.0 × 10
10 CFU of either STEC or stx-negative E. coli K-12 
(K-12) twice per week from 2 weeks pre- to 16 weeks 376    Witold A. Ferens et al.
Fig. 1. Low Shiga toxin-producing Escherichia coli (STEC) score
correlated with poor health at the advanced stage of bovine 
leukemia virus (BLV) infection. STEC scores were calculated 
form 6 samples (average logarithm of CFU/g feces, multiplied by
proportion of STEC- positive samples). The horizontal broken 
line separates low (STEC score ≤ 1.5) from high (STEC score ≥
2.3) rank. Animals presenting with symptoms of poor health are 
indicated by letter “P”, and letter “T” indicates an animal with 
tumors. 
post-BLV challenge. Group 1 received 5 wild-type ovine 
STEC of different serotypes; group 2 received K-12 prior 
to BLV challenge, and then STEC beginning at 1 day post 
BLV challenge; groups 3 and 4 never received STEC. 
Fecal STEC numbers were determined as described 
previously [9] by isolation of CFU on hydrophobic-grid 
filters [20] and colony hybridization with stx-specific 
DNA probes [13] by a modified procedure of Nizetic et al. 
[16]. Carriage of STEC over time was compared among 
individual animals using an STEC score = (the average 
logarithms of STEC CFU/g feces × the proportion of 
STEC-positive samples). STEC measurements from June 
to September (3 × before and 3 × post BLV) exceeded 10
7 
CFU/g in some sheep, but subsequent positive samplings 
showed only 10
2∼10
4 CFU/g feces. Since values ＜ 10
4 
CFU/g feces were previously shown to have no antiviral 
effect [9], STEC treatment was discontinued in October. 
BLV challenge
  Sheep in groups 1, 2, and 3 were injected subcutaneously 
with single doses of 1.0 × 10
6 peripheral blood mononuclear 
cells (PBMC) from a BLV-positive cow. Group 3 was the 
STEC-untreated, BLV-infected control and Group 4 (no 
BLV) was the STEC-untreated, BLV-uninfected control. 
Flow cytometry and histology 
  B cells in whole blood samples were identified by standard 
flow cytometry with murine monoclonal antibodies against 
B-cell markers B-B1 (BAS9A, IgM) and B-B2 (BAQ44A, 
IgM) (VMRD, USA) and secondary antibody conjugate 
(Caltag/Invitrogen, USA) [5]. Animals were killed by 
intravenous injection of potassium barbiturate at 12∼14 
months post BLV challenge, and autopsied. Gross 
pathology was noted, and tissue samples preserved in 4% 
buffered formaldehyde. Sections of lymph nodes (retropharyngeal, 
prescapular, submandibular, and mesentheric) were stained 
with hematoxylin-eosin and scored from 0∼4 for neoplasia 
by a veterinary pathologist unfamiliar with the treatment 
assignments. 
Statistical analysis
  Health status, pathology, and total B lymphocytes were 
analyzed independent of STEC treatment, among STEC 
treatment groups independent of STEC numbers, and 
between BLV-infected and BLV-free sheep carrying only 
naturally occurring STEC (i.e. not STEC treated). Statistical 
significance was assessed by non-parametric tests, and 
differences among experimental groups were assessed by 
analysis of variance (ANOVA). Analyses used Minitab 13 
software (Minitab, USA). 
Results
    Low STEC scores correlated with poor condition of 
BLV-infected sheep. BLV-challenged sheep could be 
separated into two distinct subpopulations: those with STEC 
scores ＜ 1.5 or ＞ 2.3 (Fig. 1). All animals in poor health 
had low STEC scores (Chi-square test, DF = 1, p = 0.004) 
and failed to carry ≥ 10
4 CFU/g more than once post BLV 
challenge. Also, these 4 animals never carried ≥ 4.5 log 
CFU STEC/g after BLV challenge, whereas two sheep (1412 
and 1395) with low STEC scores < 1.5, that remained in good 
condition, had one fecal sample with ≥ 4.5 log CFU STEC/g 
after BLV challenge. Thus, carriage of ≥ 4.5 log CFU/g of 
intestinal STEC at least once during the early phase of 
infection appeared to protect sheep from BLV- induced 
disease for up to 12∼14 months. Likewise, consistently low 
numbers of STEC (＜ 10
4 CFU/g) prior to and during the 
initial 2 months post BLV challenge were associated with 
deteriorating health. In the absence of BLV infection, low 
STEC scores were not associated with poor health. 
    STEC scores correlated with weight gain among the 
BLV-challenged sheep. At 6 months post BLV challenge 
(after 2 months of consistent weight gain by all BLV- 
negative control sheep), 9 animals with STEC score ＞ 2.3 
averaged 87.0 ± 2.6 kg, while 6 animals with STEC score 
＜ 1.5 averaged 75.0 ± 3.0 kg (p = 0.001, Mood median 
test). Among the STEC-treated groups 1 and 2, weight 
correlated weakly with STEC scores, but the correlation 
was strong in group 3 animals, carrying only naturally 
acquired STEC (Pearson coefficient 0.891, p = 0.042) 
(Fig. 2A). In the absence of BLV infection, STEC scores 
did not correlate with weight (Fig. 2B). 
  At autopsy, average lymph node neoplasia scores ranged 
from 1.8 to 2.2 for all sheep. Only one animal, 1424, STEC carriage and prognosis of BLV infection in sheep    377
Fig. 4. Peak B-cell percentages differentially correlated with Shiga
toxin-producing Escherichia coli (STEC) scores. (A) % B-cells in
bovine leukemia virus (BLV)-challenged sheep were negatively
correlated with STEC scores. (B) % B-cells from BLV-free control
sheep were positively correlated with STEC scores. 
Fig. 2. Weight gain in sheep challenged with bovine leukemia virus 
(BLV) correlated with Shiga toxin-producing Escherichia coli
(STEC) scores. Weight at 6 months post BLV challenge is plotted 
against STEC scores. (A) BLV-challenged sheep, (B) control sheep. 
Points in panel A were fitted with a second-power polynomial curve.
Fig. 3. Shiga toxin-producing Escherichia coli (STEC) treatment 
correlated with percentages of B cells in blood. Data are group 
averages + SEM of B cell percentages. A bracket indicates group
1 significantly different from control (ANOVA, p ＜ 0.05). 
presented an average lymph node score of 4.0, indicating 
the presence of a tumor in all lymph nodes examined, and 
with copious tumors located in the intestinal wall, and 
other tissues. This animal had the lowest fecal STEC 
counts post-BLV (0 to ＜ 10
3 CFU/g feces). 
    Intestinal STEC differentially influenced the B-cell 
percentage in peripheral blood by BLV status. The 
percentages of B cells among PBMC from BLV-challenged 
sheep underwent major fluctuations indicative of viral 
expansion and immune suppression of viremia. The mean 
B-cell percentage post-BLV challenge was 39.6% ± 2.5% 
among all BLV-infected animals, higher than the control 
sheep mean (32.2% ± 4.5). In a majority of BLV infected 
sheep (11/15) values ranged from 52.4 to 70.5%, above the 
median value 50.9% for control animals. Among group 1 
animals, the B-cell percentages were consistently higher 
than among the control animals (Fig. 3, bracketed time- 
points, p = 0.031, ANOVA). Peak B-cell percentage was 
noted at 5 weeks after commencement of STEC treatment 
in group 1 and at 6 weeks in group 2, suggesting that STEC 
treatment stimulated B-cell production in animals from both 
STEC-treated groups. In groups 3 and 4, that never received 
STEC treatment, correlations between STEC scores and 
maximal B-cell percentages were diametrically opposed: 
positive in BLV-free group 4 (Pearson coefficient = 0.986, 
p = 0.014) and negative in BLV-challenge group 3 (Pearson 
coefficient = -0.944, p = 0.016) (Fig. 4). 
Discussion
  Absence of disease in sheep exhibiting STEC scores ＞  2.3 
agrees with our previous finding that carriage of ＞ 10
4 CFU 
STEC/g feces for 2 months post challenge reduces early 
BLV viremia [9]. Suppression of early viremia may allow 
an effective immune response or STEC carriage at BLV 
challenge may influence interferon-γ and/or interleukin 
12-dependent pathways, known to correlate with resistance 
to BLV [12]. STEC-associated weight gain in BLV-positive 
animals points to possible beneficial impact of STEC upon 
host physiology, beyond a strict antiviral effect. 
    STEC carriage was positively correlated with B-cell 
percentage in BLV-free animals, and negatively correlated 
in BLV-positive sheep, but only in a group that did not receive 
STEC. Thus, STEC may stimulate B-cell proliferation. In 
BLV-challenged animals this effect of STEC could be 
masked by STEC-mediated elimination of B cells harboring 
BLV. Although proviral BLV DNA was reported in T cells, 
monocytes, and other cell types, it appears that the virus is 
expressed only in B cells [15,18], and can stimulate these 378    Witold A. Ferens et al.
cells to proliferate [6]. Thus, two opposing STEC-related 
factors, i.e. stimulation of B-cell expansion and elimination 
of BLV-positive B cells could confound the analysis of the 
impact of BLV infection and STEC carriage on B-cell 
percentages, especially in STEC-treated sheep. Moreover, 
B-cell expansion by STEC treatment increased the 
availability of BLV cellular targets, putting the sheep from 
groups 1 and 2 at a long-term disadvantage and making them 
more vulnerable to BLV, especially after cessation of STEC 
treatment at 4 months and removal of protective effects of 
Stxs, present in and/or produced by inocula. This conjecture 
is consistent with the lack of correlation between STEC 
scores and weight gain in groups 1 and 2, as opposed to group 
3, and with the clustering of cases of poor health and tumor 
in group 1, that exhibited already elevated B-cell percentage 
upon BLV challenge. 
  Conclusions: 1) Elevated numbers of intestinal STEC 
carried at and after BLV challenge correlated with protection 
from BLV disease. High STEC scores were associated with 
good health and weight gain, and low STEC scores with poor 
health and low weight gain, among BLV-infected sheep. 2) 
Repeated oral treatments with STEC were associated with 
increased percentages of B cells in peripheral blood, 
although treatment did not consistently increase the 
numbers of fecal STEC. 3) STEC score provided a means 
of expressing time-averaged STEC colonization in sheep 
and was used effectively in statistical analysis. 4) The 
correlation between STEC score and B-cell percentage in 
blood was positive in BLV-free sheep, and negative in 
BLV-challenged sheep harboring only naturally acquired 
STEC. These results suggest that intestinal STEC can 
stimulate B-cell expansion. In BLV-positive animals, STEC 
presence may contribute to elimination of toxin-sensitive B 
cells harboring BLV, thereby reducing viral loads and 
disease progression. 
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